BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 8358719)

  • 1. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
    Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP; Zhou W; Longnecker DS; Jensen RT; Mantey SA; Bell RH
    Gastroenterology; 1994 Oct; 107(4):1135-46. PubMed ID: 7523219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth of azaserine-induced putative preneoplastic nodules in the rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
    Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
    Ann N Y Acad Sci; 1994 Mar; 713():439-41. PubMed ID: 8018216
    [No Abstract]   [Full Text] [Related]  

  • 4. Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas.
    Douglas BR; Woutersen RA; Jansen JB; de Jong AJ; Rovati LC; Lamers CB
    Cancer Res; 1989 May; 49(9):2438-41. PubMed ID: 2706631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas.
    Bell RH; Kuhlmann ET; Jensen RT; Longnecker DS
    Cancer Res; 1992 Jun; 52(12):3295-9. PubMed ID: 1596887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization.
    Zhou W; Povoski SP; Longnecker DS; Bell RH
    Cancer Res; 1992 Dec; 52(24):6905-11. PubMed ID: 1458479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas.
    Lhoste EF; Longnecker DS
    Cancer Res; 1987 Jun; 47(12):3273-7. PubMed ID: 3581068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine.
    Sumi C; Longnecker DS; Roebuck BD; Brinck-Johnsen T
    Cancer Res; 1989 May; 49(9):2332-6. PubMed ID: 2706621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic localization of cholecystokinin (CCK) receptor expression during the development of azaserine-induced rat pancreatic carcinoma.
    Tsuei BJ; Povoski SP; Zhou W; Bell RH
    Pancreas; 1996 Nov; 13(4):401-6. PubMed ID: 8899801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dietary fats and soybean protein on azaserine-induced pancreatic carcinogenesis and plasma cholecystokinin in the rat.
    Roebuck BD; Kaplita PV; Edwards BR; Praissman M
    Cancer Res; 1987 Mar; 47(5):1333-8. PubMed ID: 3815341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells.
    Dawra R; Saluja A; Lerch MM; Saluja M; Logsdon C; Steer M
    Biochem Biophys Res Commun; 1993 Jun; 193(3):814-20. PubMed ID: 8323557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition by retinoids of the growth of azaserine-induced foci in the rat pancreas.
    Roebuck BD; Baumgartner KJ; Thron CD; Longnecker DS
    J Natl Cancer Inst; 1984 Jul; 73(1):233-6. PubMed ID: 6610790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the behavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide.
    Crawley JN; St-Pierre S; Gaudreau P
    J Pharmacol Exp Ther; 1984 Aug; 230(2):438-44. PubMed ID: 6086888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of azaserine-induced pancreatic foci by phenolic antioxidants in rats.
    Roebuck BD; MacMillan DL; Bush DM; Kensler TW
    J Natl Cancer Inst; 1984 Jun; 72(6):1405-10. PubMed ID: 6610071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal expression of the gastrin (CCK-B) receptor during azaserine-induced pancreatic carcinogenesis.
    Povoski SP; Zhou W; Longnecker DS; Bell RH
    Pancreas; 1993 Sep; 8(5):615-21. PubMed ID: 8302799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643.
    Obourn JD; Frame SR; Bell RH; Longnecker DS; Elliott GS; Cook JC
    Toxicol Appl Pharmacol; 1997 Aug; 145(2):425-36. PubMed ID: 9266817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas.
    Visser CJ; Rijksen G; Woutersen RA; De Weger RA
    Lab Invest; 1996 Jan; 74(1):2-11. PubMed ID: 8569183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
    Povoski SP; Zhou W; Longnecker DS; Bell RH
    Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.